AbbVie Says All Three Zumilokibart Dose Regimens Met Primary Endpoint With Significantly Greater EASI-75 Response Vs Placebo At Week 16 In Phase 2 APEX Part B Atopic Dermatitis Study

AbbVie announced that all three dose regimens of its drug zumilokibart met the primary endpoint in a Phase 2 study for atopic dermatitis, showing significantly greater EASI-75 response rates compared to placebo at Week 16. The mid-dose regimen has been selected for Phase 3 development to further evaluate its efficacy, safety, and dosing profile. Zumilokibart is a half-life extended monoclonal antibody targeting IL-13.